ADC Therapeutics SA (NYSE:ADCT) — Stock Price
ADC Therapeutics SA (NYSE:ADCT) is currently trading at $1.13 USD, up 0.00% today. Over the past 52 weeks, shares have ranged between $0.98 and $4.88. This page tracks ADC Therapeutics SA's live share price on the NYSE exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see ADC Therapeutics SA market cap and net worth.
ADC Therapeutics SA (ADCT) Stock Price Chart — Daily History & Trading Volume
The chart below tracks ADC Therapeutics SA's daily closing share price and trading volume on the NYSE exchange over the past year, giving a clear view of recent price momentum and liquidity.
ADC Therapeutics SA Income Statement — Revenue, Profit & Earnings by Year
ADC Therapeutics SA's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Revenue | $81.36 Million | $70.84 Million | $69.56 Million | $209.91 Million | $33.92 Million |
| Cost of Revenue | $7.67 Million | $5.95 Million | $2.53 Million | $3.30 Million | $1.39 Million |
| Gross Profit | $73.68 Million | $64.89 Million | $67.03 Million | $206.61 Million | $32.52 Million |
| Research & Development | $104.00 Million | $109.63 Million | $127.13 Million | $186.46 Million | $158.00 Million |
| SG&A | $36.56 Million | $64.47 Million | $72.88 Million | $107.74 Million | $71.46 Million |
| Total Operating Expenses | $182.06 Million | $195.54 Million | $233.01 Million | $329.95 Million | $294.24 Million |
| Operating Income | $-108.38 Million | $-130.65 Million | $-165.99 Million | $-123.34 Million | $-261.72 Million |
| EBITDA | $-106.50 Million | $-102.65 Million | $-145.83 Million | $-107.70 Million | $-230.53 Million |
| EBIT | $-108.38 Million | $-105.92 Million | $-149.09 Million | $-110.09 Million | $-233.16 Million |
| Interest Expense | $51.63 Million | $50.21 Million | $46.33 Million | $36.73 Million | $18.34 Million |
| Income Before Tax | $-142.78 Million | $-157.68 Million | $-200.95 Million | $-156.90 Million | $-251.50 Million |
| Income Tax Expense | $-157.00K | $166.00K | $39.11 Million | $227.00K | $-21.48 Million |
| Net Income | $-142.62 Million | $-157.85 Million | $-240.05 Million | $-157.13 Million | $-230.03 Million |
ADC Therapeutics SA Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes ADC Therapeutics SA's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Assets | $323.15 Million | $321.98 Million | $354.78 Million | $490.86 Million | $617.97 Million |
| Total Current Assets | $306.33 Million | $307.39 Million | $336.29 Million | $434.98 Million | $525.18 Million |
| Cash & Equivalents | — | — | — | — | — |
| Short-term Investments | — | — | — | — | — |
| Net Receivables | $29.12 Million | $20.32 Million | $25.18 Million | $72.97 Million | $32.17 Million |
| Inventory | $4.18 Million | $18.39 Million | $16.18 Million | $12.07 Million | $11.12 Million |
| Property, Plant & Equipment | — | — | — | $9.98 Million | $11.23 Million |
| Goodwill | — | — | — | — | — |
| Total Liabilities | $508.98 Million | $524.62 Million | $503.03 Million | $411.41 Million | $451.88 Million |
| Total Current Liabilities | $70.16 Million | $80.47 Million | $67.67 Million | $81.94 Million | $73.94 Million |
| Long-term Debt | $112.45 Million | $113.63 Million | $112.73 Million | $97.24 Million | $125.10 Million |
| Net Debt | $177.67 Million | $-127.87 Million | $-154.22 Million | $-196.59 Million | $-326.85 Million |
| Total Stockholder Equity | $-185.83 Million | $-202.64 Million | $-148.25 Million | $79.45 Million | $166.09 Million |
| Retained Earnings | $-1.64 Billion | $-1.49 Billion | $-1.34 Billion | $-1.10 Billion | $-924.88 Million |
ADC Therapeutics SA Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how ADC Therapeutics SA generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Cash Flow | $-141.17 Million | $-123.83 Million | $-118.69 Million | $-138.31 Million | $-233.38 Million |
| Capital Expenditures | $264.00K | $867.00K | $3.22 Million | $687.00K | $6.38 Million |
| Free Cash Flow | $-141.44 Million | $-124.70 Million | $-121.90 Million | $-139.00 Million | $-239.75 Million |
| Investing Cash Flow | $395.00K | $-867.00K | $-3.22 Million | $-687.00K | $-6.67 Million |
| Financing Cash Flow | $150.94 Million | $97.05 Million | $73.88 Million | $-897.00K | $267.39 Million |
| Dividends Paid | — | — | — | — | — |
| Stock-Based Compensation | $6.91 Million | $6.57 Million | $13.49 Million | $50.64 Million | $60.48 Million |
| Depreciation | $1.88 Million | $3.28 Million | $3.27 Million | $5.74 Million | $2.63 Million |
| Change in Cash | $10.47 Million | $-27.73 Million | $-47.84 Million | $-140.10 Million | $27.35 Million |
ADC Therapeutics SA Earnings History — EPS Actual vs. Analyst Estimates
Track ADC Therapeutics SA's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| Aug 05, 2026 | — | -0.21 | — |
| May 04, 2026 | -0.21 | -0.20 | -5.00% |
| Mar 12, 2026 | -0.04 | -0.30 | +86.59% |
| Nov 10, 2025 | -0.30 | -0.36 | +16.67% |
| Aug 12, 2025 | -0.50 | -0.48 | -4.17% |
| May 05, 2025 | -0.36 | -0.41 | +13.11% |
| Mar 27, 2025 | -0.29 | -0.41 | +29.27% |
| Nov 07, 2024 | -0.42 | -0.39 | -7.69% |